,trastuzumab deruxtecan
Daiichi Sankyo,AstraZeneca
['mbc', 'congrat', 'paradigm']
and there you have it. db04 shows impressive pfs and os improvement in her2 low mbc. ild of 12% is not to be disregarded. all in all a paradigm shift. congratulations to dr modi and colleagues. great news for patients. #asco22 
#BreastCancer Chief Oncologist | Researcher | Executive Medical Director @BCMCancerCenter @StLukesHealthTX | Innovation | Access to care | Views are my own